Clerkenwell Health, a psychedelic-specialist clinical research organisation, has raised £2.1m in seed funding, bringing the total to date up to £2.5m, which will be used to get the London startup-based fully operational.
Investors include Lionheart Ventures, Convergence Partners, and Exceptional Ventures, which was co-founded by Paolo Pio (former MD Europe at Joyance Partners) and Matt Cooper (who was part of the founding team at Capital One Bank in the US, co-founder of Tandem Bank and Chairman of Octopus Capital Group).
Claiming to be Europe’s first commercial facility dedicated to psychede
コメント